drugset
drugset / Trial / NCT05631249

Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C

NCT05631249 ↗

Phase 2 Recruiting 40 enrolled Gustave Roussy, Cancer Campus, Grand Paris
NaSingle-groupOpen-labelTreatment

Summary

This study aims to provide a comprehensive understanding of sotorasib's mechanisms of action and resistance in NSCLC patients.

Timeline

Start
2022-12-13
Primary completion
2027-12-12
Completion
2027-12-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Sotorasib Small molecule 120 mg Oral

Indications

acute myeloid leukemia, KRAS gene mutation non-small cell lung carcinoma